BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31132976)

  • 1. An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase.
    M S; B P; Swaminathan P
    Curr Comput Aided Drug Des; 2020; 16(3):340-350. PubMed ID: 31132976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
    Hurt DE; Sutton AE; Clardy J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
    Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
    Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
    DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
    Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
    Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
    Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
    Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
    Berber B; Doluca O
    Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
    Heidarian R; Zahedi-Tabrizi M
    Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
    Leban J; Vitt D
    Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors.
    Bonomo S; Tosco P; Giorgis M; Lolli M; Fruttero R
    J Mol Model; 2013 Mar; 19(3):1099-107. PubMed ID: 23143678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
    Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
    J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dihydroorotate dehydrogenase (DHODH) inhibitors on the growth of Theileria equi and Babesia caballi in vitro.
    Kamyingkird K; Cao S; Tuvshintulga B; Salama A; Mousa AA; Efstratiou A; Nishikawa Y; Yokoyama N; Igarashi I; Xuan X
    Exp Parasitol; 2017 May; 176():59-65. PubMed ID: 28286324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
    Kim TH; Na HS; Löffler M
    Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
    McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
    Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
    Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
    Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
    Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
    Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
    Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
    Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.